Get the Stockscreener App
4.73
2.27%
-0.11
After Hours:
4.55
-0.18
-3.81%
Arbutus Biopharma Corp stock is traded at $4.73, with a volume of 806.06K.
It is down -2.27% in the last 24 hours and up +4.19% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.84
Open:
$4.85
24h Volume:
806.06K
Relative Volume:
0.73
Market Cap:
$906.73M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-10.75
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+8.49%
1M Performance:
+4.19%
6M Performance:
+33.24%
1Y Performance:
+23.02%
1-Day Range:
$4.71
$4.905
1-Week Range:
$4.30
$4.945
52-Week Range:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.73 | 927.82M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Why Arbutus Biopharma Corporation (I9DN) stock stays undervalued - newser.com
Will Arbutus Biopharma Corporation stock recover faster than marketJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Quantitative breakdown of Arbutus Biopharma Corporation recent moveQuarterly Portfolio Summary & Long-Term Safe Investment Plans - newser.com
Signal strength of Arbutus Biopharma Corporation stock in tech scannersWeekly Trend Recap & Technical Analysis for Trade Confirmation - newser.com
Can Arbutus Biopharma Corporation stock deliver surprise earnings beat2025 Trading Recap & Reliable Breakout Forecasts - newser.com
Arbutus Biopharma Corporation (ABUS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Can Arbutus Biopharma Corporation stock continue upward trend2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Custom strategy builders for tracking Arbutus Biopharma CorporationGDP Growth & Daily Entry Point Trade Alerts - newser.com
Arbutus Biopharma (ABUS) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Can Arbutus Biopharma Corporation stock sustain revenue growthForecast Cut & Advanced Technical Analysis Signals - newser.com
Intraday pattern recognizer results for Arbutus Biopharma Corporation2025 Geopolitical Influence & Reliable Volume Spike Alerts - newser.com
Arbutus Biopharma Corporation stock trend outlook and recovery pathPortfolio Gains Report & Daily Growth Stock Investment Tips - newser.com
Is this a good reentry point in Arbutus Biopharma Corporation2025 Institutional Moves & Fast Gaining Stock Strategy Reports - newser.com
Can Arbutus Biopharma Corporation stock resist market sell offsShort Setup & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
Aug Mood: Can Arbutus Biopharma Corporation stock continue upward trendRate Cut & Weekly Watchlist of Top Performers - fcp.pa.gov.br
Is it time to cut losses on Arbutus Biopharma CorporationJuly 2025 Movers & Daily Risk Controlled Trade Plans - newser.com
What technical signals suggest for Arbutus Biopharma Corporation stockEarnings Growth Report & High Accuracy Buy Signal Tips - fcp.pa.gov.br
Will Arbutus Biopharma Corporation (I9DN) stock see insider accumulationShort Setup & Accurate Entry/Exit Alerts - newser.com
Arbutus Biopharma’s (ABUS) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
How Arbutus Biopharma Corporation (I9DN) stock trades under stagflationMarket Activity Summary & Free High Return Stock Watch Alerts - newser.com
What to do if you’re stuck in Arbutus Biopharma CorporationQuarterly Trade Review & Capital Efficient Trade Techniques - newser.com
Published on: 2025-10-26 22:31:52 - newser.com
Can Arbutus Biopharma Corporation stock attract ESG capital inflowsWeekly Trade Report & Weekly Breakout Opportunity Watchlist - newser.com
Arbutus Biopharma to Present New Data on Imdusiran and AB-101 at AASLD 2025 - MSN
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):